RxDoctor Payments Data

Kyle Bolo

Ophthalmology · Los Angeles, CANPI 1154984417

Payments from drug & device makers

$4,613in general payments, 2019–2025

Across 61 payments — averaging $75.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$1K
  • Glaukos Corporation$263
  • Sight Sciences, Inc.$246
  • NEW World Medical,inc.$154
  • Alimera Sciences, Inc.$144
  • plus $466 from 5 others

What the payments were for

  • Travel & lodging$2265%
  • Food & beverage$4,38795%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,613 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$20,530
Medicare patients
109
Services billed
189

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate79$35,752
LumiganBimatoprost48$25,405
Alphagan PBrimonidine Tartrate32$10,575
Latanoprost606$10,206
Travoprost43$9,212
RestasisCyclosporine12$8,205
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol55$7,346
Brimonidine Tartrate141$6,578
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat278$6,549
RocklatanNetarsudil Mesylat/Latanoprost12$5,894
Brinzolamide34$5,562
CombiganBrimonidine Tartrate/Timolol21$5,297
Dorzolamide-TimololDorzolamide/Timolol/Pf34$4,510
SimbrinzaBrinzolamide/Brimonidine Tart16$3,905
Prednisolone Acetate75$3,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Restasis, Combigan$1,997$49,482113 claims
AlconSimbrinza$1,342$3,90516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →